Switching GLP-1 medications: what the labels say
The short answer
If you're switching GLP-1 medications, know that no FDA label converts a dose of one medicine into a dose of a different one. The labels give switching steps only between Wegovy injection and Wegovy tablets, between Rybelsus and Ozempic tablets, and from Ozempic 0.5 mg injection to semaglutide tablets. For every other switch, the new label states one starting dose and your prescriber decides.
Key takeaways
- No FDA label converts a dose between two different GLP-1 medicines. Be wary of any chart that does.
- The labels describe only three switches, and all of them are between semaglutide products from Novo Nordisk.
- The Wegovy, Zepbound, Saxenda and Foundayo labels say using two GLP-1 medicines together isn't recommended.
- With commercial insurance, an approval and a savings card stay with the old brand. Expect a new prior authorization.
- Before your appointment, write down your last dose, its date, and any side effects you had at that dose.
On this page
- What do the FDA labels say about switching?
- Why is there no dose conversion between different medicines?
- What does your prescriber decide?
- Can you take two GLP-1 medicines at once?
- How does switching change what you pay?
- How does switching change your coverage?
- What if you are changing form, not medicine?
- What if there is a gap between medicines?
- Guides to specific switches
- Frequently asked questions
- Sources
People switch GLP-1 medicines for everyday reasons. A plan stops covering one. A pharmacy can’t fill it. The price changes, side effects don’t settle, or a prescriber thinks a different medicine fits better. The first thing most people want to know is which dose of the new medicine matches the old one. For different medicines, the FDA labels don’t answer that, and this guide explains what they say instead. Every statement below comes from the prescribing information published on DailyMed.
The switching planner shows what the labels say and the price difference for any pair of medicines we track.
What do the FDA labels say about switching?
They describe three switches, all between semaglutide products made by Novo Nordisk. Everything else is left to your prescriber.
- Wegovy injection and Wegovy tablets. The Wegovy label has a section on moving between its own two forms. Adults on the 2.4 mg weekly injection for weight reduction or cardiovascular risk reduction may switch to the 25 mg tablet, starting it one week after the last injection. People on the 25 mg tablet may switch to the injection, starting 2.4 mg once weekly the day after the last tablet. See Wegovy pen to Wegovy pill and Wegovy pill to Wegovy pen.
- Rybelsus and Ozempic tablets. These two tablets share one label. It says they can’t be swapped milligram for milligram, and that no switch should happen in the first 30 days of treatment. After that, Rybelsus 7 mg matches Ozempic tablets 4 mg, and Rybelsus 14 mg matches Ozempic tablets 9 mg. See Rybelsus to the Ozempic pill.
- Ozempic injection to semaglutide tablets. The same tablet label says people on the 0.5 mg dose of Ozempic injection may switch to Rybelsus (7 mg or 14 mg) or Ozempic tablets (4 mg or 9 mg), starting one week after the last injection. It gives no steps for any other Ozempic injection dose.
That’s the full list in the labels we hold. The Zepbound, Mounjaro, Foundayo, Trulicity, Saxenda and Ozempic injection labels give no steps for switching from another GLP-1 medicine. Each one only states its own starting dose.
Why is there no dose conversion between different medicines?
Because no label has one. A label’s dosing section describes how that one product was studied and approved: a starting dose, a schedule for raising it, and a top dose. None of the labels for Zepbound, Mounjaro, Foundayo, Trulicity, Saxenda or Ozempic injection says that a certain dose of some other medicine equals a certain dose of its own.
The labels are careful even within one molecule. Rybelsus and Ozempic tablets both contain semaglutide, yet their shared label still says you can’t swap them milligram for milligram. Wegovy injection is dosed in single milligrams once a week, and Wegovy tablets in tens of milligrams once a day. Milligram numbers don’t carry across products, forms or molecules.
That’s why this site never converts a dose from one medicine to another, and why you should be wary of any chart that does. What we can show you is what each label states:
- Zepbound and Mounjaro (tirzepatide): 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks on the current dose.
- Wegovy injection: 0.25 mg once weekly, raised every 4 weeks through the label’s dose table.
- Wegovy tablets: 1.5 mg once daily for the first 30 days.
- Ozempic injection: 0.25 mg once weekly for 4 weeks.
- Ozempic tablets: 1.5 mg once daily for days 1 through 30. Rybelsus: 3 mg once daily for days 1 to 30.
- Saxenda: 0.6 mg daily for one week, then weekly increases.
The label describes the first step on each ladder. Your prescriber writes the prescription.
What does your prescriber decide?
Almost everything the label leaves open:
- The dose you’re prescribed. The label gives a starting dose and a schedule. How your time on another medicine affects that is a medical judgment. Neither a label nor this site can settle it.
- The timing. Outside the three semaglutide switches above, no label says how long to wait between the last dose of one medicine and the first dose of the next.
- Whether the new medicine is approved for your condition. Ozempic, Mounjaro and Rybelsus are approved for adults with type 2 diabetes. Wegovy, Zepbound and Saxenda are approved for weight reduction, and Zepbound also for obstructive sleep apnea in adults with obesity. A switch can move you from one approved use to another, and that matters for coverage.
- Your other medicines. The Zepbound and Mounjaro labels say to consider lowering the dose of insulin or a sulfonylurea (a type of diabetes pill) when starting, to lower the risk of low blood sugar. They also advise people on birth control pills to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.
Bring a short list to your appointment: the medicine, the strength and the date of your last dose, the side effects you had and at which dose, every other medicine you take, and what your plan has told you about coverage.
Can you take two GLP-1 medicines at once?
The labels say it isn’t recommended. A switch replaces one medicine with the other. It never overlaps them.
- The Wegovy label says use with other semaglutide-containing products, or with any other GLP-1 receptor agonist, isn’t recommended.
- The Zepbound label says the same about other tirzepatide-containing products and any GLP-1 receptor agonist.
- The Saxenda label says it about other liraglutide-containing products and any other GLP-1 receptor agonist.
- The Foundayo label says use with another GLP-1 receptor agonist isn’t recommended.
If you have leftover pens or tablets of the old medicine, ask your pharmacist how to get rid of them. Don’t use them alongside the new prescription.
How does switching change what you pay?
Three things change at once: the price at each dose, the program you buy through, and any savings card.
Self-pay prices differ by medicine and by dose. Zepbound vials through LillyDirect cost $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and above when you refill within 45 days. Wegovy pens through NovoCare cost $199 a month for the first two fills of the two lowest doses if you’re new to the offer, then $349. Wegovy tablets cost $149 to $299. Ozempic pens cost $349 a month at 0.5 mg and 1 mg after the new-patient fills, and $499 at 2 mg. Mounjaro is $499 a month at every strength.
A lower starting price isn’t the whole story. If you’re prescribed the label’s starting dose, your first fills of the new medicine may cost less than a maintenance fill (the dose you stay on) of the old one, and then go up. The cost calculator adds up a full year on each medicine, and the GLP-1 cost guide lists every way to buy.
Savings cards don’t transfer. Each manufacturer card is tied to one brand, and to commercial insurance that covers that brand. With coverage, the Wegovy, Ozempic, Zepbound and Mounjaro cards each bring a fill down to as little as $25. After a switch, you sign up for the new brand’s card, if you qualify. The savings card guide has the terms.
Refill timing rules start over. LillyDirect’s lower price for Zepbound 7.5 mg and above depends on refilling within the window. If you move to Zepbound, read about the 45-day rule before your second fill.
How does switching change your coverage?
Coverage follows the drug and the diagnosis, not the drug class.
Commercial insurance. Your plan decides brand by brand. An approval for one medicine doesn’t carry over to another, so expect a new prior authorization. Check the plan’s formulary (its list of covered drugs) for the new brand before your prescriber writes the prescription. Moving from a diabetes medicine to a weight-management medicine is the change most likely to hit an exclusion, because a plan’s rules for weight-management drugs can differ from its rules for diabetes drugs.
Medicare Part D. The Part D law excludes drugs when they’re used for weight loss. CMS lists type 2 diabetes, moderate to severe obstructive sleep apnea and MASH as uses that can be covered under Part D. So a switch from Ozempic or Mounjaro for diabetes to Wegovy or Zepbound for weight loss changes which rules apply to you.
The Medicare GLP-1 Bridge. The Bridge covers Wegovy (injection or tablet), Foundayo and the Zepbound KwikPen for weight management at a $50 copay. Ozempic and Mounjaro aren’t on its list, and people with type 2 diabetes aren’t eligible. A Bridge approval covers refills and dose changes, but you need a new prior authorization if you switch to a different covered GLP-1. The Bridge guide has the full criteria.
What if you are changing form, not medicine?
Changing the device within one brand is a different question. The Zepbound and Mounjaro labels give no dose conversion between the vial, the single-dose pen and the KwikPen. They say only that if your prescribed form changes, you should be trained on the new one and read its Instructions for Use. The Wegovy label says the same about its single-dose pen, syringe and FlexTouch pen. The pen, vial or pill tool compares the forms and their prices.
What if there is a gap between medicines?
Supply problems and prior authorizations can leave weeks between your last dose of one medicine and your first dose of the next. The labels cover gaps only within their own product. The Wegovy label says to restart the dose increases at a lower dose if 2 or more weekly injections in a row are missed. The Saxenda label says to restart at 0.6 mg daily if more than 3 days have passed since the last dose. Neither says what a gap means for starting a different medicine. Tell your prescriber the date of your last dose. The missed dose tool covers each label’s own rules.
Guides to specific switches
Each guide sets out what both labels say, the new medicine’s starting dose, the price before and after, and what to ask your prescriber.
From Ozempic:
Between weight-management medicines:
Between forms of semaglutide:
For the medicines themselves, start with the hubs for Zepbound, Mounjaro, Wegovy, Ozempic, Rybelsus and Saxenda.
Frequently asked questions
Can you switch from one GLP-1 to another?
Yes, with a new prescription, and the decision is your prescriber's. The FDA labels describe only a few switches, all within semaglutide products. For a switch between different medicines, such as Ozempic to Mounjaro or Wegovy to Zepbound, the new medicine's label gives no switching steps. It states one starting dose, and your prescriber decides how that applies to you.
Is there a dose conversion chart for switching GLP-1 medications?
Not in any FDA label for a switch between different medicines. The only label table that pairs doses is for Rybelsus and Ozempic tablets: Rybelsus 7 mg with Ozempic tablets 4 mg, and Rybelsus 14 mg with Ozempic tablets 9 mg. Charts that turn a semaglutide dose into a tirzepatide dose don't come from a label, and we don't publish one.
What dose do you start at when switching from Ozempic to Mounjaro?
The Mounjaro label gives one starting dose, 2.5 mg once weekly, and no steps for people coming from another GLP-1 medicine. It doesn't convert an Ozempic dose into a Mounjaro dose. What you're prescribed, and when you take your first injection after your last Ozempic dose, is up to your prescriber.
Do you have to start over at the lowest dose when you switch?
The labels don't answer that for a switch between different medicines. Each one states a starting dose and a schedule for raising it, and none says how earlier treatment with another GLP-1 changes that. Where a label does describe a switch, as between Wegovy injection and Wegovy tablets, it names the exact doses. Ask your prescriber what applies to you.
Can you take two GLP-1 medications at the same time while switching?
The labels say not to. The Wegovy, Zepbound, Saxenda and Foundayo labels each say that using them with another GLP-1 receptor agonist isn't recommended. Wegovy, Zepbound and Saxenda also name other products that contain their own ingredient. So a switch means one medicine ends and the other begins, on the timing your prescriber sets.
How long do you wait between stopping one GLP-1 and starting another?
The labels give a gap only for the switches they describe. Wegovy 25 mg tablets start one week after the last 2.4 mg injection, and the injection starts the day after the last tablet. Rybelsus and Ozempic tablets swap the next day. For a switch between different medicines, no label states a gap, so ask your prescriber for the exact dates.
Will my insurance cover the new medication if I switch?
Not automatically. Coverage follows the drug and the reason it's prescribed. A plan that pays for Ozempic or Mounjaro for type 2 diabetes may not pay for Wegovy or Zepbound for weight loss. Expect a new prior authorization, which is the plan's approval before it pays. Savings cards are tied to one brand too, so the card you have now won't work on the new medicine.
Is it cheaper to switch GLP-1 medications?
Sometimes. Self-pay prices start at $149 a month for Wegovy and $299 for Zepbound, while Mounjaro is $499 a month through LillyDirect at every strength. Starting doses are often the cheapest fills, so compare prices at the dose you expect to stay on, not just the first month.
Sources (25)
- 1.FDA label (DailyMed): Wegovy prescribing information, section 2.5
“One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.”
- 2.FDA label (DailyMed): Wegovy prescribing information, section 2.5
“The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly.”
- 3.FDA label (DailyMed): Wegovy prescribing information, section 1
“Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
- 4.FDA label (DailyMed): Zepbound prescribing information, section 1
“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 5.FDA label (DailyMed): Saxenda prescribing information, section 1
“SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 6.FDA label (DailyMed): Foundayo prescribing information, section 1
“Concomitant use with another GLP-1 receptor agonist is not recommended.”
- 7.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.”
- 8.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.3
“When switching between RYBELSUS and OZEMPIC tablets, initiate the other semaglutide tablet product the day after discontinuing the previous semaglutide tablet product.”
- 9.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.4
“One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 4 mg or 9 mg of OZEMPIC tablets orally once daily.”
- 10.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.4
“One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 7 mg or 14 mg of RYBELSUS orally once daily.”
- 11.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Inform patients and their caregiver(s) which ZEPBOUND presentation (e.g., vial, prefilled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed ZEPBOUND presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”
- 12.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“Inform patients and their caregiver(s) which MOUNJARO presentation (e.g., vial, pre-filled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed MOUNJARO presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”
- 13.FDA label (DailyMed): Saxenda prescribing information, section 2.1
“If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1, to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.”
- 14.FDA label (DailyMed): Zepbound prescribing information, section 8.3
“Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
- 15.FDA label (DailyMed): Mounjaro prescribing information, section 8.3
“Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
- 16.FDA label (DailyMed): Zepbound prescribing information, section 7.1
“ZEPBOUND lowers blood glucose. When initiating ZEPBOUND, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia [see Warnings and Precautions (5.7)].”
- 17.FDA label (DailyMed): Mounjaro prescribing information, section 7.1
“When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3)].”
- 18.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
- 19.CMS: Information for Part D Plans
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
Related pages
- What is Zepbound? Uses, cost, doses and side effects
- Mounjaro (tirzepatide): uses, cost, doses and side effects
- What is Wegovy? Uses, doses, pill and pen, and cost
- What is Ozempic? Uses, doses, cost and how to take it
- Rybelsus (semaglutide tablets): uses, doses, cost and how to take it
- Saxenda (liraglutide): uses, doses, cost and how to take it
